Cancer vaccines: current status and future directions
Abstract Cancer continues to be a major global health burden, with high morbidity and mortality. Building on the success of immune checkpoint inhibitors and adoptive cellular therapy, cancer vaccines have garnered significant interest, but their clinical success remains modest. Benefiting from advan...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-02-01
|
| Series: | Journal of Hematology & Oncology |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s13045-025-01670-w |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849715729991991296 |
|---|---|
| author | Yingqiong Zhou Yuquan Wei Xiaohe Tian Xiawei Wei |
| author_facet | Yingqiong Zhou Yuquan Wei Xiaohe Tian Xiawei Wei |
| author_sort | Yingqiong Zhou |
| collection | DOAJ |
| description | Abstract Cancer continues to be a major global health burden, with high morbidity and mortality. Building on the success of immune checkpoint inhibitors and adoptive cellular therapy, cancer vaccines have garnered significant interest, but their clinical success remains modest. Benefiting from advancements in technology, many meticulously designed cancer vaccines have shown promise, warranting further investigations to reach their full potential. Cancer vaccines hold unique benefits, particularly for patients resistant to other therapies, and they offer the ability to initiate broad and durable T cell responses. In this review, we highlight the antigen selection for cancer vaccines, introduce the immune responses induced by vaccines, and propose strategies to enhance vaccine immunogenicity. Furthermore, we summarize key features and notable clinical advances of various vaccine platforms. Lastly, we delve into the mechanisms of tumor resistance and explore the potential benefits of combining cancer vaccines with standard treatments and other immunomodulatory approaches to improve vaccine efficacy. |
| format | Article |
| id | doaj-art-2b8bdff61d24439cab0941ed06c33072 |
| institution | DOAJ |
| issn | 1756-8722 |
| language | English |
| publishDate | 2025-02-01 |
| publisher | BMC |
| record_format | Article |
| series | Journal of Hematology & Oncology |
| spelling | doaj-art-2b8bdff61d24439cab0941ed06c330722025-08-20T03:13:14ZengBMCJournal of Hematology & Oncology1756-87222025-02-0118113010.1186/s13045-025-01670-wCancer vaccines: current status and future directionsYingqiong Zhou0Yuquan Wei1Xiaohe Tian2Xiawei Wei3Laboratory of Aging Research and Cancer Drug Target, State Key Laboratory of Biotherapy, National Clinical Research Center for Geriatrics, West China Hospital, Sichuan UniversityLaboratory of Aging Research and Cancer Drug Target, State Key Laboratory of Biotherapy, National Clinical Research Center for Geriatrics, West China Hospital, Sichuan UniversityLaboratory of Aging Research and Cancer Drug Target, State Key Laboratory of Biotherapy, National Clinical Research Center for Geriatrics, West China Hospital, Sichuan UniversityLaboratory of Aging Research and Cancer Drug Target, State Key Laboratory of Biotherapy, National Clinical Research Center for Geriatrics, West China Hospital, Sichuan UniversityAbstract Cancer continues to be a major global health burden, with high morbidity and mortality. Building on the success of immune checkpoint inhibitors and adoptive cellular therapy, cancer vaccines have garnered significant interest, but their clinical success remains modest. Benefiting from advancements in technology, many meticulously designed cancer vaccines have shown promise, warranting further investigations to reach their full potential. Cancer vaccines hold unique benefits, particularly for patients resistant to other therapies, and they offer the ability to initiate broad and durable T cell responses. In this review, we highlight the antigen selection for cancer vaccines, introduce the immune responses induced by vaccines, and propose strategies to enhance vaccine immunogenicity. Furthermore, we summarize key features and notable clinical advances of various vaccine platforms. Lastly, we delve into the mechanisms of tumor resistance and explore the potential benefits of combining cancer vaccines with standard treatments and other immunomodulatory approaches to improve vaccine efficacy.https://doi.org/10.1186/s13045-025-01670-wCancer vaccineTumor antigenClinical outcomeTumor resistanceCombination therapy |
| spellingShingle | Yingqiong Zhou Yuquan Wei Xiaohe Tian Xiawei Wei Cancer vaccines: current status and future directions Journal of Hematology & Oncology Cancer vaccine Tumor antigen Clinical outcome Tumor resistance Combination therapy |
| title | Cancer vaccines: current status and future directions |
| title_full | Cancer vaccines: current status and future directions |
| title_fullStr | Cancer vaccines: current status and future directions |
| title_full_unstemmed | Cancer vaccines: current status and future directions |
| title_short | Cancer vaccines: current status and future directions |
| title_sort | cancer vaccines current status and future directions |
| topic | Cancer vaccine Tumor antigen Clinical outcome Tumor resistance Combination therapy |
| url | https://doi.org/10.1186/s13045-025-01670-w |
| work_keys_str_mv | AT yingqiongzhou cancervaccinescurrentstatusandfuturedirections AT yuquanwei cancervaccinescurrentstatusandfuturedirections AT xiaohetian cancervaccinescurrentstatusandfuturedirections AT xiaweiwei cancervaccinescurrentstatusandfuturedirections |